Atsushi Nagayasu

Kitakyushu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Zero Time-to-Echo Imaging of the Hand and Wrist in Rheumatoid Arthritis Patients.

Zero Time-to-Echo Imaging of the Hand and Wrist in Rheumatoid Arthritis Patients.

Journal: Journal of magnetic resonance imaging : JMRI

Published: April 13, 2026

Effectiveness and Safety of Sarilumab in Polymyalgia Rheumatica: a retrospective study of the FIRST Registry.

Effectiveness and Safety of Sarilumab in Polymyalgia Rheumatica: a retrospective study of the FIRST Registry.

Journal: Modern rheumatology

Published: December 05, 2025

Short-chain fatty acid deficiency drives aberrant B cell differentiation in systemic lupus erythematosus.

Short-chain fatty acid deficiency drives aberrant B cell differentiation in systemic lupus erythematosus.

Journal: Clinical immunology (Orlando, Fla.)

Published: December 05, 2025

Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry.

Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry.

Journal: RMD open

Published: November 17, 2025

Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.

Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.

Journal: RMD open

Published: November 08, 2025

Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.

Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.

Journal: RMD open

Published: November 04, 2025

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long-term multicenter observational study.

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long-term multicenter observational study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 06, 2025

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.

Journal: Rheumatology and therapy

Published: March 04, 2025

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.

Journal: Rheumatology and therapy

Published: November 22, 2024

Real-World Safety and Efficacy of Targeted Therapies in Rheumatoid Arthritis: A 5-Year, 5130-Case Follow-Up from FIRST Registry.

Real-World Safety and Efficacy of Targeted Therapies in Rheumatoid Arthritis: A 5-Year, 5130-Case Follow-Up from FIRST Registry.

Journal: Rheumatology and therapy

Published: November 14, 2024

Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus.

Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus.

Journal: RMD open

Published: May 25, 2024

Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study.

Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study.

Journal: Rheumatology and therapy

Published: April 07, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026